Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EKF Diagnostics Holdings ( (GB:EKF) ) has shared an announcement.
EKF Diagnostics Holdings plc reported a stable revenue of £25.2 million for the first half of 2025, with improvements in gross margins and cash generation, aligning with management expectations. The company saw significant growth in its hematology and β-HB sectors, with revenues increasing by 8% and 12% respectively, and is optimistic about future contract manufacturing and fermentation opportunities, indicating a positive trajectory in its strategic development plan.
The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
Spark’s Take on GB:EKF Stock
According to Spark, TipRanks’ AI Analyst, GB:EKF is a Outperform.
EKF Diagnostics Holdings shows a solid overall performance driven by strong financial health and positive technical indicators. The strategic corporate actions, such as share buybacks and increased major shareholder confidence, also play a significant role. The main risk is the declining revenue trend, which should be monitored closely.
To see Spark’s full report on GB:EKF stock, click here.
More about EKF Diagnostics Holdings
EKF Diagnostics Holdings plc is an AIM-listed global diagnostics company specializing in point-of-care analyzers for hematology and diabetes, as well as life sciences services that include the manufacture of enzymes and custom products for diagnostic, food, and industrial applications. The company is headquartered in Penarth, near Cardiff, and operates five manufacturing sites in the US and Germany, selling to over 120 countries worldwide.
Average Trading Volume: 335,597
Technical Sentiment Signal: Hold
Current Market Cap: £119M
Find detailed analytics on EKF stock on TipRanks’ Stock Analysis page.